Successful salvage treatment of chronic refractory immune thrombocytopenia using a simplified method to generate vincristine-loaded platelets

Oliver Weigert; Georg Wittmann; Stefanie Gruetzner; Jitske Cnossen; Marie-Christine Becker; Martin Dreyling; Helmut Ostermann

doi:10.1160/TH08-03-0177

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2008; 100(04): 705-707
DOI: 10.1160/TH08-03-0177

Case Report

Schattauer GmbH

Successful salvage treatment of chronic refractory immune thrombocytopenia using a simplified method to generate vincristine-loaded platelets

Oliver Weigert

¹Department of Internal Medicine III, University Hospital of Munich, Grosshadern, Munich, Germany

,

Georg Wittmann

²Department of Transfusion Medicine and Haemostaseology, University Hospital of Munich, Grosshadern, Munich, Germany

,

Stefanie Gruetzner

²Department of Transfusion Medicine and Haemostaseology, University Hospital of Munich, Grosshadern, Munich, Germany

,

Jitske Cnossen

¹Department of Internal Medicine III, University Hospital of Munich, Grosshadern, Munich, Germany

,

Marie-Christine Becker

¹Department of Internal Medicine III, University Hospital of Munich, Grosshadern, Munich, Germany

,

Martin Dreyling

¹Department of Internal Medicine III, University Hospital of Munich, Grosshadern, Munich, Germany

,

Helmut Ostermann

¹Department of Internal Medicine III, University Hospital of Munich, Grosshadern, Munich, Germany

References
1 Davoren A, Bussel J, Curtis BR. et al. Prospective evaluation of a new platelet glycoprotein (GP)-specific assay (PakAuto) in the diagnosis of autoimmune thrombocytopenia (AITP). Am J Hematol 2005; 78: 193-197.
2 Facon T, Caulier MT, Fenaux P. et al. Accessory spleen in recurrent chronic immune thrombocytopenic purpura. Am J Hematol 1992; 41: 184-189.
3 Andersen JC. Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy. N Engl J Med 1994; 330: 1560-1564.
4 Godeau B, Porcher R, Fain O. et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura – results of a prospective multicenter phase 2 study. Blood. 2008 in print.
5 Arnold DM, Dentali F, Crowther MA. et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007; 146: 25-33.
6 Emilia G, Luppi M, Zucchini P. et al. Helicobacter pylori infection and chronic immune thrombocytopenic purpura: long-term results of bacterium eradication and association with bacterium virulence profiles. Blood 2007; 110: 3833-3841.
7 Brox AG, Howson-Jan K, Fauser AA. Treatment of idiopathic thrombocytopenic purpura with ascorbate. Br J Haematol 1988; 70: 341-344.
8 Reiner A, Gernsheimer T, Slichter SJ. Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. Blood 1995; 85: 351-358.
9 Figueroa M, Gehlsen J, Hammond D. et al. Combination chemotherapy in refractory immune thrombocytopenic purpura. N Engl J Med 1993; 328: 1226-1229.
10 McMillan R. Long-term outcomes after treatment for refractory immune thrombocytopenic purpura. N Engl J Med 2001; 344: 1402-1403.
11 Ahn YS, Byrnes JJ, Harrington WJ. et al. The treatment of idiopathic thrombocytopenia with vinblastine-loaded platelets. N Engl J Med 1978; 298: 1101-1107.
12 Agnelli G, DeCunto M, Gresele P. et al. Vincristineloaded platelets for autoimmune thrombocytopenic purpura. Blood 1982; 60: 1235.
13 Ganti AK, Landmark JD, Kessinger A. et al. Vin cristineladen platelet transfusion for patients with refractory thrombocytopenia. In Vivo 2006; 20: 559-563.
14 Shvidel L, Sigler E, Shtalrid M, Berrebi A. Vincristine-loaded platelet infusion for treatment of refractory autoimmune hemolytic anemia and chronic immune thrombocytopenia: rethinking old cures. Am J Hematol 2006; 81: 423-425.
15 Stasi R, Evangelista ML, Stipa E. et al. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost 2008; 99: 4-13.
16 Ahn YS, Harrington WJ, Seelman RC. et al. Vincristine therapy of idiopathic and secondary thrombocytopenias. N Engl J Med 1974; 291: 376-380.
17 Facon T, Caulier MT, Wattel E. et al. A randomized trial comparing vinblastine in slow infusion and by bolus i.v. injection in idiopathic thrombocytopenic purpura: a report on 42 patients. Br J Haematol 1994; 86: 678-680.
18 Bensch KG, Malawista SE. Microtubule crystals: a new biophysical phenomenon induced by Vinca alkaloids. Nature 1968; 218: 1176-1177.
19 Gout PW, Wijcik LL, Beer CT. Differences between vinblastine and vincristine in distribution in the blood of rats and binding by platelets and malignant cells. Eur J Cancer 1978; 14: 1167-1178.
20 Kelton JG, McDonald JW, Barr RM, Walker I, Nicholson W, Neame PB. et al. The reversible binding of vinblastine to platelets: implications for therapy. Blood 1981; 57: 431-438.
21 Rosse WF. Whatever happened to vinca-loaded platelets?. N Engl J Med 1984; 310: 1051-1052.